Literature DB >> 35798832

Androgen receptor pathway inhibitor combination in prostate cancer.

Kelvin Yan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35798832     DOI： 10.1038/s41585-022-00623-z

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   16.430


× No keyword cloud information.
  3 in total

1.  Darolutamide in Metastatic Prostate Cancer. Reply.

Authors:  Matthew R Smith
Journal:  N Engl J Med       Date:  2022-06-16       Impact factor: 91.245

2.  What is fuelling the monkeypox outbreak?

Authors:  Annette Fenner
Journal:  Nat Rev Urol       Date:  2022-10       Impact factor: 16.430

Review 3.  Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.

Authors:  Mike Wenzel; Luigi Nocera; Claudia Collà Ruvolo; Christoph Würnschimmel; Zhe Tian; Shahrokh F Shariat; Fred Saad; Derya Tilki; Markus Graefen; Luis A Kluth; Alberto Briganti; Philipp Mandel; Francesco Montorsi; Felix K H Chun; Pierre I Karakiewicz
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-05-30       Impact factor: 5.455
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.